ERBB2 and triple-negative breast carcinoma: Higher detection rates were observed in cases with HER2+ (100%, 2/2) and triple-negative breast cancer (TNBC) (88%, 7/8) disease, followed by HR+/HER2− (52%, 11/21) positive subtype (Figure 1A).